"Merck Foundation More Than a Mother" is a strong movement that aims to empower infertile and childless women through access to information, education and change of mindset. "I am thrilled to ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other psychedelic stocks. In contrast to drugs like cocaine or marijuana, psychedelics are ...

As Merck & Co. hunts for an ideal spot to set up a new commercial facility, Delaware is looking to bolster its odds with a cash sweetener. Monday, Delaware’s state investment board approved a $ ...

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...

Mer­ck said its “once-in-a-life­time” drug Keytru­da could be sub­ject to price re­duc­tions un­der the In­fla­tion Re­duc­tion Act, which would lead to a … ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication developed by Merck that has raked in more than $130 billion in sales for the ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer ...